

FOI 2857

22nd January 2025

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

Response:

Abatacept [Orencia]	90
Adalimumab [Humira]	30
Adalimumab Biosimilars	586
Apremilast [Otezla] -	1
Baricitinib [Olumiant]	42
Bimekizumab [Bimzelx]	1
Certolizumab [Cimzia]	73
Etanercept [Enbrel]	9
Etanercept Biosimilars	214
Filgotinib [Jyseleca]	0
Golimumab [Simponi]	75
Guselkumab [Tremfya]	16
Infliximab [Remicade]	1
Infliximab Biosimilars	30
Ixekizumab [Taltz]	55
Risankizumab [Skyrizi]	4
Rituximab [MabThera]	0
Rituximab Biosimilars	132
Sarilumab [Kevzara]	21
Secukinumab [Cosentyx]	155
Tocilizumab [Ro Actemra]	47

Tocilizumab Biosimilars	7
Tofacitinib [Xeljanz]	8
Upadacitinib [Rinvoq]	26
Ustekinumab [Stelara]	0
Ustekinumab Biosimilar	0

Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs:

Response:

Abatacept [Orencia]	0
Adalimumab [Humira]	12
Adalimumab Biosimilars	200
Apremilast [Otezla]	0
Bimekizumab [Bimzelx]	0
Certolizumab [Cimzia]	30
Etanercept [Enbrel]	3
Etanercept Biosimilars	65
Golimumab [Simponi]	27
Guselkumab [Tremfya]	16
Infliximab [Remicade]	0
Infliximab Biosimilars	11
Ixekizumab [Taltz]	38
Risankizumab [Skyrizi]	4
Secukinumab [Cosentyx]	96
Tofacitinib [Xeljanz]	4
Upadacitinib [Rinvoq]	4
Ustekinumab [Stelara]	0
Ustekinumab Biosimilar	0

Email: Foi.Team@Southerntrust.hscni.net